Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Delivery room caffeine treatment for very preterm infants feasibility study
2018-003626-91Phase 2Completed
- Sponsor
- Azienda Ospedaliero-Universitaria Careggi
- Start
- Nov 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of caffeine in respiratory distress syndrome (RDS) (2 arms), sponsored by Azienda Ospedaliero-Universitaria Careggi. Primary endpoint: Successful caffeine administration within first 10 minutes of life. Started Nov 2020; status: completed.
02
Drugs
caffeine
03
Conditions
respiratory distress syndrome (RDS)
Beyond the preview
Go deeper on 2018-003626-91.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-003626-91.